Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›Global X›2639

2639

Global X Japan Bio & Med Tech ETF

Passive ETF Equity Theme: Healthcare Technology & Innovation Theme: Tomorrow's Treatments

Not rated

The 2639 Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: FactSet Japan Bio & Med Technologies Index. The 2639 ETF provides physical exposure, so by buying it you actually own parts of all the 31 underlying holdings. This share class generates a stream of income by distributing dividends.

¥1,779

-¥80 (-4.30%) today

12:00 AM 08/25/26 Closed

1D price range

¥1,764¥1,899

52W price range

¥1,580.21¥1,796.69

YTD Perf.

+8.35%

YTD Flows

Annualized volatility

Fund AuM

€1.7M

Share class AuM

€1.7M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

JP3049310000

TER

0.649%

Inception date

6/23/2021

Issuer

Global X

Benchmark

FactSet Japan Bio & Med Technologies Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

No content available for this fund

API

PerformanceDec 30, 2025 - Aug 21, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

92.79%

Technology

7.05%

Unavailable

0.16%

Latest 2639 news

No content available for this fund

FAQ about 2639

2639 is a Passive ETF. This ETF provides exposure to Japanese Equities.

2639 tracks the FactSet Japan Bio & Med Technologies Index (PR) - JPY, through a optimized sampling replication method.

2639 carries a total expense ratio (TER) of 0.649%, indicating the annual cost for holding the fund.

2639 was introduced to the market on June 23, 2021. It trades on Japan

Global X Japan Bio & Med Tech ETF, 2639, is provided by Global X. Learn more about Global X here.

2639 oversees €1.7M in assets as of August 21, 2026.

2639 follows a distributing dividend policy, meaning it pays out income to investors. As of August 21, 2026, its 12-month trailing yield was 3.16%.

As of June 30, 2026, 2639 has significant geographic allocations in Japan.

As of June 30, 2026, 2639 focuses largely on Healthcare and Technology.

As of June 30, 2026, 2639 holds 31 positions in its portfolio, with 82.14% of assets concentrated in its top 15 holdings.

As of June 30, 2026, 2639 top three holdings include Terumo Corp., Asahi Intecc Co., Ltd. and Shionogi & Co., Ltd..

The base currency of 2639 is JPY.

Top 10 holdings

Data as of 06/30/26

Terumo Corp.

8.29%

Asahi Intecc Co., Ltd.

8.11%

Shionogi & Co., Ltd.

8.10%

Shimadzu Corp.

8.07%

M3, Inc.

7.05%

Sysmex Corp.

6.90%

Olympus Corp.

6.84%

Takeda Pharmaceutical Co., Ltd.

6.13%

Otsuka Holdings Co., Ltd.

3.78%

Chugai Pharmaceutical Co., Ltd.

3.69%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

Global X Japan Bio & Med Tech ETF

FAQ about 2639

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US